Impact of immunosuppressants on SARS-CoV-2 infection in elderly patients with inflammatory bowel disease.
Aging Clin Exp Res
; 33(8): 2355-2359, 2021 Aug.
Article
en En
| MEDLINE
| ID: mdl-34164799
ABSTRACT
BACKGROUND:
Older age has been reported as a risk factor for severe SARS-CoV-2 disease (COVID-19). The impact of immunosuppressants (IMS) on COVID-19 is still under debate.AIM:
To describe the incidence and severity of COVID-19 in elderly patients with inflammatory bowel disease (IBD) in relation to the use of IMS.METHODS:
IBD patients over 65 years of age were selected and grouped in terms of IMS use. Confirmed COVID-19, adherence to IST, comorbidities and concomitant non-IBD-related treatments between 1st of March 2020 to 1st of March 2021 were recorded.RESULTS:
Out of 418 patients included, 89 (21.3%) were on IMS. Thirty-two patients (7.7%) had COVID-19, 7 of whom were on IMS (7.6% not on IMS vs. 7.9% on IMS; P = 0.933) and 7 (22%) patients died.CONCLUSIONS:
Incidence of COVID-19 among elderly IBD patients was similar to that reported in the background population, regardless of the use of IMS.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Enfermedades Inflamatorias del Intestino
/
COVID-19
Tipo de estudio:
Etiology_studies
/
Risk_factors_studies
Límite:
Aged
/
Humans
Idioma:
En
Revista:
Aging Clin Exp Res
Asunto de la revista:
GERIATRIA
Año:
2021
Tipo del documento:
Article
País de afiliación:
España